ERA4TB: The development of anti-tuberculosis drug combinations
ERA4TB is expected to revolutionise the way tuberculosis treatments are developed, thanks to its parallelised, multi-entry pipeline structure—analogous to a production line. This structure will enable the systematic investigation of the efficacy of several drug candidates and combinations simultaneously, while allowing new molecules to enter the project pipeline at the research stage, corresponding to the degree of knowledge gathered on those candidate drugs prior to the project.
How does ERA4TB accelerate drug development?
With its approach, the ERA4TB consortium expects to reduce the time required for the development of new tuberculosis treatment regimens by up to 25%.
The ERA4TB initiative integrates more than thirty organisations from the European Union and the United States, including key global actors in the fight against tuberculosis.
ERA4TB began in 2020 and will last six years, at the end of which the consortium expects to have developed at least two or more new combination regimens with treatment-shortening potential, ready for Phase II clinical evaluation. The partners intend to maintain the ERA4TB platform beyond the official duration of the project.
Across the consortium, ERA4TB has built and validated a shared preclinical-to-clinical toolkit: the Hollow Fibre System for TB (HFS-TB), recognised by the European Commission’s Innovation Radar; a seven-laboratory EUCAST drug susceptibility testing network; granuloma-like structure (GLS) and host-pathogen interaction (HPI) assay platforms; advanced imaging techniques including time-lapse microscopy and PET-CT; animal models spanning mice, marmosets and macaques; a coordinated Phase I clinical trial network; and AI-driven PK/PD modelling and simulation capabilities. These sit alongside shared data infrastructure – the Drug Development Information Management (DDIM) System and the C-Path Data Archive with its TB-PACTS and TB-APEX platforms.
As of August 2026, over 6 years since the project began, the ERA4TB pipeline had grown to 14 molecules in progress, with in vivo, in vitro, preclinical development and First-in-Human studies running in parallel across the portfolio. In November 2024, the University of Zaragoza’s implementation of the Hollow Fibre System won a Spanish national Quality Innovation Award in the ‘innovation with potential’ category, going on to win the equivalent international award.
What are ERA4TB’s objectives?
The main objective of ERA4TB is to create a European open platform to accelerate the development of new regimens for the treatment of tuberculosis. To reach this goal, the consortium has set the following specific objectives:
- Implementation of state-of-the-art tools and capacities into an open platform for the evaluation of TB drug candidates to effectively progress compounds from early preclinical to clinical development and identify potential new Pan-tuberculosis (Pan-TB)1 regimens ready for Phase II clinical evaluation.
- Development of modelling and simulation tools and application of standard and new artificial intelligence (AI) techniques for better characterization of pharmacokinetic-pharmacodynamic (PK/PD) relationships (concentration-effect or exposure-response relationships depending on the trial), optimization of clinical trial design, prediction of therapeutic dose range and antibacterial activity in humans.
- Management of data generated by the project, integrating also data and knowledge from historical datasets available in reference databases and from previous and existing consortia and projects, in the context of an ever-improving ‘learning system’ that allows to refine the platform continuously.
- Provision of a flexible and efficient management structure able to adapt to the capacity and resource allocation level required by each platform component at each stage of the project, depending on each compound’s progression and attrition dynamics and on inherent variables of the multiple combination assays.
- Provide a sustainability plan that incorporates all the synergies and lessons learned within the project and secures the survival of the platform beyond the life of the project.
- Define and execute an outreach, engagement, dissemination and communication plan in collaboration with regulatory authorities and other stakeholders, including patient organizations, to maximize the impact of the project.
What has ERA4TB achieved so far?
The ERA4TB Hollow Fiber Infection Model for TB, the ERA4TB EUCAST Drug Susceptibility Testing Network and the ERA4TB Granuloma-Like Structure (GLS) and Host-Pathogen Interaction (HPI) Assays have been used to screen and prioritise candidate compounds and combinations, with the ERA4TB PK/PD Modelling and Simulation Platform translating these results into dose and regimen predictions for clinical testing.
Through the ERA4TB Phase I Clinical Trial Network, TBAJ-587 (TB Alliance) has completed its Phase I studies and the Phase I clinical trial final report for GSK286 (GSK) has been submitted, drawing on data managed through the ERA4TB Drug Development Information Management (DDIM) System and the ERA4TB Data from Clinical TB Trials and Preclinical Experiments (TB-PACTS & TB-APEX). ERA4TB also operates a two-way relationship with UNITE4TB, the AMR Accelerator’s TB clinical-stage project: ERA4TB’s preclinical data informs UNITE4TB’s Phase II development, while clinical results feedback to refine ERA4TB’s translational tools.
Access ERA4TB resources
ERA4TB resources are linked from this page. They have also been integrated into the AMR Accelerator results catalogues and published in scientific journals,
ERA4TB publications in scientific journals
-
Nedelman J, Conradie A, Lombardi A, Hickman D, Abd-Elaziz K, Dogterom P, Bruinenberg P, Carcas Sansuán AJ, Sakiman E, Diamant Z, van Duinen J, Beumont M, Sun E. Pharmacokinetics and safety of TBAJ-587, a novel antimycobacterial diarylquinoline, in healthy participants. Antimicrobial Agents and Chemotherapy. 2026 Jul 28:e0193025. doi:10.1128/aac.01930-25
-
Aguilar-Ayala DA, Rabodoarivelo MS, Eveque-Mourroux MR, Leding AAM, Sonnenkalb L, Picó Marco A, Willand N, Serbina N, Simonsson USH, Lucía A, Ramón-García S; ERA4TB consortium. In vitro pharmacokinetics and pharmacodynamics of the diarylquinoline TBAJ-587 and its metabolites against Mycobacterium tuberculosis. Frontiers in Microbiology. 2026. doi:10.3389/fmicb.2026.1828998
-
Leding AAM, Bruinenberg P, Conradie A, Nedelman J, Lombardi A, Hickman D, Simonsson USH. Population pharmacokinetics of TBAJ-587 and its main metabolites — evaluation of different loading dose strategies and early dose selection. British Journal of Clinical Pharmacology. 2026;92(4):1058-1068. doi:10.1002/bcp.70333
-
Calvet-Seral J, Sáez-López E, López-Expósito PR, Ferrer-Bazaga S, Vaquero JJ, Ramón-García S, Mendoza-Losana A. The ribosomal RNA synthesis ratio biomarker in Mycobacterium ulcerans for drug activity evaluation. Infectious Diseases of Poverty. 2026;15:51. doi:10.1186/s40249-026-01449-2
-
Iavarone L, Lavezzi SM, Carcas AJ, Chaychenko T, Gabarro-Carrion R, Gómez López de las Huertas A, Gresham S, Marín-Candón A, Penman SL, Rolfe K, Tiberi S, Barros-Aguirre D, Borobia AM; ERA4TB consortium. Combined oral contraceptive drug-drug interaction study with ganfeborole, a new anti-tuberculosis agent. Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70161
- Raaijmakers J, Sanz-García F, Sadouki Z, Aguilar-Ayala DA, Mead A, Readman JB, et al. Use of hollow fiber systems to model treatment of infections: a practical guide. iScience. 2026;29:115535. doi:10.1016/j.isci.2026.115535
-
Visuña L, Garcia-Blas J, Ferrer-Bazaga S, Lopez-Exposito P, Carretero J. Automated monitoring of Mycobacterium population growth in time-lapse microscopy with Deep Learning pseudo-supervised algorithm. Engineering Applications of Artificial Intelligence. 2025;162:112503. doi:10.1016/j.engappai.2025.112503
- Karakitsios E, della Pasqua O, Dokoumetzidis A. Extrapolation of lung pharmacokinetics of bedaquiline across species using physiologically-based pharmacokinetic modelling. British Journal of Clinical Pharmacology. 2025;91(11). doi:10.1002/BCP.70163
- Rabodoarivelo MS, Hoffmann E, Gaudin C, et al. Protocol to quantify bacterial burden in time-kill assays using colony-forming units and most probable number readouts for Mycobacterium tuberculosis. STAR Protocols. 2025;6(1):103643. doi:10.1016/j.xpro.2025.103643
- Fernow J, Olliver M, Couet W, et al. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Nature Reviews Drug Discovery. 2024. doi:10.1038/d41573-024-00138-9
- Gries R, Chhen J, van Gumpel E, et al. Discovery of dual-active ethionamide boosters inhibiting the Mycobacterium tuberculosis ESX-1 secretion system. Cell Chemical Biology. 2024;31(4):699-711.e6. doi:10.1016/j.chembiol.2023.12.007
- Nagar S, Nicholls D, Dawoud D, et al. A systematic review of economic evaluations of pharmacological treatments for active tuberculosis. Frontiers in Public Health. 2024;12:1201512. doi:10.3389/FPUBH.2024.1201512
- Aguilar-Ayala DA, Sanz-García F, et al. Evaluation of critical parameters in the hollow-fibre system for tuberculosis: A case study of moxifloxacin. British Journal of Clinical Pharmacology. 2024. doi:10.1111/BCP.16068
- Moraga P, Prieto P, Conradie A, et al. Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units. Clinical and Translational Science. 2023;16(12):2421-2428. doi:10.1111/CTS.13655
- van Wijk RC, Lucía A, Sudhakar PK, et al. Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium. iScience. 2023;26(4):106411. doi:10.1016/j.isci.2023.106411
- Toniolo C, Dhar N, McKinney JD. Uptake-independent killing of macrophages by extracellular Mycobacterium tuberculosis aggregates. The EMBO Journal. 2023;42(9). doi:10.15252/embj.2023113490
- Mishra R, Hannebelle M, Patil VP, et al. Mechanopathology of biofilm-like Mycobacterium tuberculosis cords. Cell. 2023;186(23):5135-5150.e28. doi:10.1016/j.cell.2023.09.016
- Gries R, Dal Molin M, Chhen J, et al. Characterization of two novel inhibitors of the Mycobacterium tuberculosis cytochrome bc1 complex. Antimicrobial Agents and Chemotherapy. 2023;67(7). doi:10.1128/aac.00251-23
- Cañadas-Ortega M, Gómez-Cruz C, Vaquero JJ, Muñoz-Barrutia A. The role of diagnostic microdevices in the fight against tuberculosis. In: Integrated Science. 2023. doi:10.1007/978-3-031-15955-8_7
- Mistretta M, Gangneux N, Manina G. Microfluidic dose–response platform to track the dynamics of drug response in single mycobacterial cells. Scientific Reports. 2022;12(1):1-18. doi:10.1038/s41598-022-24175-9
- Visuña L, Yang D, Garcia-Blas J, Carretero J. Computer-aided diagnostic for classifying chest X-ray images using deep ensemble learning. BMC Medical Imaging. 2022;22(1):178. doi:10.1186/s12880-022-00904-4
- Griego A, Douché T, Gianetto QG, Matondo M, Manina G. RNase E and HupB dynamics foster mycobacterial cell homeostasis and fitness. iScience. 2022;25(5):104233. doi:10.1016/j.isci.2022.104233
- Xu J, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL. Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. 2021;65(4):e02418-20. doi:10.1128/AAC.02418-20
- Basak S, Deb D, Narsaria U, Kar T, Castiglione F, Sanyal I, Bade PD, Srivastava AP. In silico designing of a vaccine candidate against Clostridium difficile. Scientific Reports. 2021;11:14805. doi:10.1038/s41598-021-93305-6
- Castiglione F, Deb D, Srivastava AP, Liò P, Liso A. From infection to immunity: understanding the response to SARS-CoV-2 through in-silico modeling. Frontiers in Immunology. 2021;12:646972. doi:10.3389/fimmu.2021.646972
- Yang D, Martinez C, Visuña L, Khandhar H, Bhatt C, Carretero J. Detection and analysis of COVID-19 in medical images using deep learning techniques. Scientific Reports. 2021;11:19638. doi:10.1038/s41598-021-99015-3
- Thacker VV, Dhar N, Sharma K, Barrile R, Karalis K, McKinney JD. A lung-on-chip model of early M. tuberculosis infection reveals an essential role for alveolar epithelial cells in controlling bacterial growth. eLife. 2020;9:e59961. doi:10.7554/eLife.59961
- Faraj A, Clewe O, Svensson RJ, Mukamolova GV, Barer MR, Simonsson USH. Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions. Scientific Reports. 2020;10:15537. doi:10.1038/s41598-020-72472-y
- Torres-Simón A, Marino MH, Gómez-Cruz C, Cañadas M, Marco M, Ripoll J, Vaquero JJ, Muñoz-Barrutia A. Development of an inverted epifluorescence microscope for long-term monitoring of bacteria in multiplexed microfluidic devices. Sensors. 2020;20(15):4140. doi:10.3390/s20154140
- Kar T, Narsaria U, Basak S, Deb D, Castiglione F, Mueller D, Srivastava A. A candidate multi-epitope vaccine against SARS-CoV-2. Scientific Reports. 2020;10:10895. doi:10.1038/s41598-020-67749-1
- Boldrin F, Provvedi R, Cioetto Mazzabò L, Segafreddo G, Manganelli R. Tolerance and persistence to drugs: a main challenge in the fight against Mycobacterium tuberculosis. Frontiers in Microbiology. 2020;11:1924. doi:10.3389/fmicb.2020.01924
Repositories
TB-PACTS—Platform for Aggregation of Clinical TB Studies (TB-PACTS, part of the C-Path Data Archive) contains data from TB clinical trials. An application is required to gain access.
Apply to access the database at the C-Path Institute website.
TB-APEX — Platform for the Aggregation of Preclinical Experiments Data (part of the C-Path Data Archive) catalogues preclinical trial data sets. Application required to gain access.
Apply to access the database at the C-Path Institute website.
Platforms
C-Path Data Archive provides access to databases/repositories containing multiple legacy TB clinical trials and preclinical experiments for ERA4TB partners, other TB consortia and qualified researchers.
Apply to access the ERA4TB data archive at the C-Path Institute website.
Drug Development Information Management (DDIM) System with procedures for acquiring, curating, and integrating internally and externally generated tuberculosis (TB) specific data sets.
Apply to access the DDIM portal services.
Protocols
Implementation of epidemiological cut-off (ECOFF) and clinical breakpoints (CBs) following the EUCAST reference method for any newly approved agents.
Read more about the protocol at the EUCAST website.
Standardised time-kill assay protocol with the most replicable and efficient plating methods, increased throughput and structured data reporting.
Read the published protocol in open access: doi:10.1016/j.isci.2023.106411.
Protocol to quantify bacterial burden in time-kill assays using colony-forming units and most probable number readouts for Mycobacterium tuberculosis. doi:10.1016/j.xpro.2025.103643
Use of hollow fiber systems to model treatment of infections: a practical guide. doi:10.1016/j.isci.2026.115535
Poster presentations
2026
- Improving the Reproducibility of RNA Sequencing Methodologies in Mycobacterium tuberculosis: A Pilot Study on Isoniazid Treatment – Trisha Parbhoo. DZIF/PEG Joint Meeting (Annual Congress of the DZIF), 23 February 2026.
- Assessment of feasibility of the hollow fibre system for PKPD studies of diarylquinolines – Fernando Sanz García. AMR Conference 2026, Basel, 2 March 2026.
- Rv0678-dependent BTZ-043 low level resistance in M. tuberculosis – understanding how to overcome it with improved combination therapies – Susanne Mesiol-Mei, Julia Dreisbach. AMR Conference 2026, Basel, 3 March 2026.
- Developing reliable minimum inhibitory concentration testing for novel drugs targeting the metabolic pathways of Mycobacterium tuberculosis, in the EUCAST microtiter broth assay – Lindsay Sonnenkalb. ESCMID Conference 2026, 17–22 April 2026.
- Impact assessment of inoculum size and recent modifications on the EUCAST reference method for MIC determination of anti-tuberculosis drugs – Lindsay Sonnenkalb. Congress of ESCMID, 17 April 2026.
- Population pharmacokinetics-driven optimization of CFU-reduction study design for boosted ethionamide combinations in mice – Chenyao Liu. Population Approach Group Europe (PAGE) 2026, 3 June 2026.
- Impact of culture media on Mycobacterium tuberculosis growth and drug efficacy – Thi Minh Nguyet Nguyen. PAGE 2026, 3 June 2026.
- Translational prediction of pharmacologically active metabolite contribution to the relative efficacy of TBAJ-587 for early clinical development – Albin Leding. PAGE 2026, 3 June 2026.
- Modeling pharmacokinetic-pharmacodynamic of PBTZ169 in glycerol and cholesterol using CFU and MPN as biomarkers – Thi Minh Nguyet Nguyen. PAGE 2026, 3 June 2026.
- A translational framework for predicting early bactericidal activity of bedaquiline and pretomanid using in vitro data – Evangelos Karakitsios. PAGE 2026, 3 June 2026.
- (Poster, event/type to confirm) Decoding Drug Efficacy and Host-Pathogen Interactions in Tuberculosis Using a Standardized In Vitro Granuloma-Like Structures Model – Enrica Campagnaro. Cortona Prokaryotes 2026, 17–19 June 2026, and re-presented at European Society of Mycobacteriology, 22–25 June 2026 (confirmed poster).
- TBD11 and GSK2556286 act as antivirulence compounds suppressing ESX-1-mediated secretion in Mycobacterium tuberculosis through Rv1625c-dependent cyclic AMP signaling – Michael Dal Molin. EMBO Workshop 2026, 14–18 September 2026.
- Assessing the Feasibility of the Hollow-Fiber System for Diarylquinoline PKPD Studies – Ainhoa Lucía Quintana. EMBO Workshop 2026, 14–18 September 2026.
- The Granuloma-Like Structure infection model: a translational tool integrating in vitro and in silico outputs for tuberculosis drug development – Greta Segafreddo. IUMS 2026, 4–6 November 2026.
- Optimizing Granuloma-Like Structures as a platform for translational tuberculosis drug development – Enrico Mastrostefano. TBScience 2026 at the Union World Lung Conference, 17–20 November 2026.
2025
- A robust and standardized progression cascade for compounds targeting host-pathogen interactions in tuberculosis – Eik Hoffmann. EMBO-FEBS Lecture Course, Blois, France, 26–30 May 2025.
- Automatic Whole Lung Segmentation Using 2.5D U-Net Approach in Mouse M. tuberculosis Infection Model – Claire J. Brooks. EMIM 2025, Bilbao, Spain, 11–14 March 2025.
- IMI ERA4TB: developing new treatment regimens for a global health threat – Katharine Cresswell. UKHSA Conference, 11 March 2025.
- A model-based approach for characterization of anti-tubercular BPaL combination therapy in vitro in different experimental conditions – Pietro Laddomada. PAGE Meeting, Greece, 4–6 June 2025.
- Do differences in pharmacokinetics overcome resemblances in immune system characteristics in cynomolgus macaques for the evaluation of antitubercular drugs? – Peter Velickovic. PAGE Meeting, Greece, 4–6 June 2025.
- Accelerating the development of novel TB therapies: innovative approaches within the public-private ERA4TB consortium hub – Santiago Ramón. Gordon Research Conference, Spain, 20–25 July 2025.
- Targeting the Tryptophan Synthase TrpAB to fight Mycobacterium tuberculosis – Maria Rosalia Pasca. World Conference on Lung Health, Denmark, 18–22 November 2025.
- The impact of phylogenetic lineage on the drug susceptibility of Mycobacterium tuberculosis – Lara Muñoz. World Conference on Lung Health, Denmark, 18–22 November 2025.
- Assessing the translational value of in vitro time-kill assays in TB drug regimens development – Sylvianne Rabodoarivelo. World Conference on Lung Health, Denmark, 18–22 November 2025.
- Investigating the Impact of Inoculum Size on EUCAST Methodology for MIC Mycobacterium tuberculosis determinations – Deborah Recchia. World Conference on Lung Health, Denmark, 18–22 November 2025.
- In vitro characterization of GSK2556286 activity in combination with Bedaquiline and Pretomanid against M. tuberculosis – Jordana Galizia. World Conference on Lung Health, Denmark, 18–22 November 2025.
- The possible role of MmpL4 in the mechanism of resistance to the new diarylquinoline TBAJ-587 – Deborah Recchia. XXXV SIMGBN Congress, Rome, Italy, 18–20 September 2025.
- Optimization of EUCAST MIC Testing for Mycobacterium tuberculosis: The Role of Inoculum Size – Deborah Recchia. XXXV SIMGBN Congress, Rome, Italy, 18–20 September 2025.
- Poster at European Researchers’ Night (Italy) – Deborah Recchia. Italian Research Night, 26 September 2025.
- Cuantificación de la carga de tuberculosis pulmonar en macacos mediante la segmentación de imágenes PET/CT – Maria de la Jara Felipe Maestre. SECAL, Bilbao, Spain, 19 November 2025.
- Integration of Molecular Biomarkers into Time-Kill Assays for Evaluating PBTZ169 Against Mycobacterium tuberculosis – Juan Calvet Seral. MycoVLC 2025, Madrid, 6–7 October 2025.
2024
- The role of MmpL4 in the mechanism of resistance to the new diarylquinoline TBAJ-587 – Maria Rosalia Pasca. ECCMID, Barcelona, Spain, 27–30 April 2024.
- PKPD de Moxifloxacin frente a M. tuberculosis demuestra la importancia de parámetros críticos en experimentos de Hollow Fiber para el desarrollo de antituberculosos – Ainhoa Lucía Quintana. XXVII Congreso SEIMC, Zaragoza, Spain, 30 May–1 June 2024.
- Semi-Automated Pipeline for Small Animal PET/CT Lung Registration and Lesion Segmentation to Assess Tuberculosis (TB) Disease Burden and Treatment Response – Claire J. Brooks, Laura Gutiérrez-de Pablo, et al. EMIM 2024, Porto, Portugal, 12–15 March 2024.
- Mycobacterium tuberculosis Tryptophan Synthase as a target for novel antitubercular drugs – Laurent Chiarelli, Giovanni Stelitano, Maria Rosalia Pasca. 48th FEBS Congress, Milan, Italy, 29 June–3 July 2024.
- An integrative translational framework for in vitro modelling of macozinone to support prediction of early human anti-tubercular efficacy – Budi Octasari Susanto. PAGE Meeting, Rome, Italy, 26–28 June 2024.
- Accelerating the development of novel TB therapies: novel in vitro profiling approaches within the public-private ERA4TB consortium hub – Maria Rosalia Pasca. IUMS 2024, Florence, Italy, 23–25 October 2024.
- A robust and standardized progression cascade for compounds targeting host-pathogen interactions in tuberculosis – Jan Rybniker. World Conference on Lung Health, Bali, Indonesia, 12–16 November 2024.
- A multicenter study to improve procedures to target the EUCAST inoculum range for Mycobacterium tuberculosis – Diana Angélica Aguilar Ayala. World Conference on Lung Health, Bali, Indonesia, 12–16 November 2024.
- An assay toolkit for the assessment of anti-TB drugs in the hollow-fibre system for tuberculosis – Fernando Sanz García, Ainhoa Lucía Quintana. World Conference on Lung Health, Bali, Indonesia, 12–16 November 2024.
- A robust and standardized progression cascade for compounds targeting host-pathogen interactions in tuberculosis – Eik Hoffmann. Congress of the French Society of Microbiology “Microbes 2024,” Lille, France, 7–9 October 2024.
- Accelerating the development of novel TB therapies: innovative approaches within the public-private ERA4TB consortium hub – Santiago Ramón. ESCMID/ASM Conference, Porto, Portugal, 17–20 September 2024.
- Enhancing anti-TB therapy: Follow-up investigations on the pheno-tuning compound M06 — Giulia Manina, with Institut Pasteur Paris. MycoDays 2024, Lille, France, 3–5 July 2024.
- Multi-stakeholder engagement in early phase tuberculosis drug development – regulators, HTA bodies and the TB community – Katharine Cresswell. FIP World Congress of Pharmacy and Pharmaceutical Sciences, South Africa, 1–4 September 2024.
- Poster at Researchers’ Night (Italy) – Maria Rosalia Pasca. Sharper Night, Italy, 27 September 2024.
- Granuloma Like Structure, a new model for evaluating the efficacy of anti-tuberculosis drugs as an alternative to macrophage monolayers – Enrico Mastrostefano. World Conference on Lung Health, Bali, Indonesia, 12–16 November 2024.
2023
- Model-based experimental design recommendations for in vivo studies of the novel anti-tuberculosis drug MPL-447 improve characterization of PK and PD – Lina Keutzer et al. PAGE Meeting, A Coruña, Spain, 28–30 June 2023.
- Protocol optimization for the evaluation of pharmacokinetics, biomarkers and efficacy of antitubercular drugs in a novel tuberculosis infection model in marmosets – Silvia Grandoni et al. PAGE Meeting, A Coruña, Spain, 28–30 June 2023.
- Pharmacokinetic Modelling of Antitubercular Drugs in Marmosets – Peter Velickovic. PAGE Meeting, A Coruña, Spain, 28–30 June 2023.
- Population pharmacokinetics of the antitubercular drug TBAJ-587 and its two main metabolites – Albin Leding. PAGE Meeting, A Coruña, Spain, 28–30 June 2023.
- Population pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations – Budi Octasari. PAGE Meeting, A Coruña, Spain, 28–30 June 2023.
- Pharmacokinetic Modelling of Antitubercular Drugs in Marmosets – Peter Velickovic. 19th World Congress of Basic & Clinical Pharmacology, Edinburgh, UK, 2–7 July 2023.
- Archimedean PET: Sensitivity Profile – Juan José Vaquero. WIMC, Prague, Czech Republic, 5–9 September 2023.
- Population pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations – Ulrika Simonsson, Budi Octasari. International Workshop on Clinical Pharmacology of Tuberculosis Drugs (virtual), 26–27 September 2023.
- In vitro efficacy of the diarylquinoline TBAJ-587 and its metabolites against Mycobacterium tuberculosis – Diana Aguilar. The Union World Conference on Lung Health, Paris, France, 15–18 November 2023.
- Manejo de ratones infectados con Mycobacterium tuberculosis en un laboratorio de imagen molecular NCB3 para PET/CT in vivo – Patricia Casado et al. (Joaquín Rullas-Trincado). SEDECAL Congress, Santiago de Compostela, Spain, 14–17 November 2023.
2022
- Handling of Mtb-infected mice in BSL3 molecular imaging laboratory for in vivo PET/CT imaging – Joaquín Rullas-Trincado et al. FELASA Congress, Marseille, France, 13–16 June 2022.
- In vitro killing dynamics of the diarylquinolone TBAJ-587 and its main metabolites against Mycobacterium tuberculosis – Diana Angélica Aguilar-Ayala et al. EMBO Workshop on Tuberculosis, Paris, France, 12–16 September 2022.
- Implementing best practices on data generation and reporting of Mycobacterium tuberculosis time-kill assays: a case study of standardized protocol within the ERA4TB consortium – Rob C. van Wijk, Ainhoa Lucía, et al. EMBO Workshop on Tuberculosis, Paris, France, 12–16 September 2022.
- Hollow Fiber System for Tuberculosis setting up at University of Zaragoza – Diana Angélica Aguilar-Ayala et al. EMBO Workshop on Tuberculosis, Paris, France, 12–16 September 2022.
- Hollow Fiber System for TB: Optimization studies with Moxifloxacin – Diana Angélica Aguilar-Ayala et al. EMBO Workshop on Tuberculosis, Paris, France, 12–16 September 2022.
- Study of the mechanism of action/resistance of antitubercular drug TBAJ-587 and its metabolites – Deborah Recchia et al. (Maria Rosalia Pasca). EMBO Workshop on Tuberculosis, Paris, France, 12–16 September 2022.
- GSK-839 inhibits the Mycobacterium tuberculosis tryptophan synthase TrpAB – Laurent Robert Chiarelli et al. (Maria Rosalia Pasca). EMBO Workshop on Tuberculosis, Paris, France, 12–16 September 2022.
2020
- Impact of IRG1 on lipid droplet formation and host immune response to control Mycobacterium tuberculosis infection – Eik Hoffmann. Virtual Keystone Symposia “Tuberculosis: Science Aimed at Ending the Epidemic,” 2–4 December 2020 (virtual).
All ERA4TB tools & resources
ERA4TB Hollow Fiber Infection Model for TB
Hollow fiber system for tuberculosis: PK/PD technology implemented to work with BSL3 pathogens. Read more about the tool at the ARAID agency website.
ERA4TB in vivo TB Infection Models
Mouse and non-human primate TB infection models implemented, with a set of non-invasive biomarkers (PET/CT imaging, cellular, cytokines, molecular biomarkers) and models to follow disease evolution and response to treatment in development.
ERA4TB Data from Clinical TB Trials and Preclinical Experiments
C-Path Data Archive provides access to databases/repositories containing multiple legacy TB clinical trials and preclinical experiments for ERA4TB partners, other TB consortia and qualified researchers. Apply to access the ERA4TB data archive at the C-Path Institute website.
ERA4TB Drug Development Information Management (DDIM) System
System with procedures for acquiring, curating, and integrating internally and externally generated tuberculosis (TB) specific data sets. Apply to access the DDIM portal services.
ERA4TB TB-PACTS (Platform for Aggregation of Clinical TB Studies)
Part of the C-Path Data Archive, TB-PACTS contains data from TB clinical trials. An application is required to gain access. Apply to access the database at the C-Path Institute website.
ERA4TB TB-APEX (Platform for the Aggregation of Preclinical Experiments Data)
Part of the C-Path Data Archive, TB-APEX catalogues preclinical trial data sets. An application is required to gain access. Apply to access the database at the C-Path Institute website.
ERA4TB ECOFF
Implementation of epidemiological cut-off (ECOFF) and clinical breakpoints (CBs) following the EUCAST reference method for any newly approved agents. Read more about the protocol at the EUCAST website.
ERA4TB Machine Learning Model
Development and assessment of a machine learning model incorporating multiple data sets (clinical, biomarkers, PK) to predict relapse-free cure of TB. Coming in 2027.
ERA4TB European Open Platform
Preclinical and Phase I European Open Platform to accelerate the development of new regimens for the treatment of TB.
ERA4TB EUCAST Drug Susceptibility Testing Network
A network of seven laboratories with regulatory-ready experimental proficiency in EUCAST drug susceptibility testing, supporting harmonised practices across the consortium.
ERA4TB Granuloma-Like Structure (GLS) and Host-Pathogen Interaction (HPI) Assays
Advanced assay platforms used for compound screening and progression decisions, alongside refined drug combination testing approaches with increased throughput.
ERA4TB Advanced Imaging Platforms
Imaging technologies including time-lapse microscopy and PET-CT, used to visualise bacterial behaviour and drug distribution in preclinical models.
ERA4TB Animal Infection Models
State-of-the-art animal testing infrastructure spanning mice, marmoset and macaque TB infection models.
ERA4TB Phase I Clinical Trial Network
A coordinated European Phase I clinical network with the capability to rapidly initiate first-in-human and combination studies, advance diagnostic evaluation, and define shared standards for future early-phase units.
ERA4TB PK/PD Modelling and Simulation Platform
AI-driven modelling and simulation capabilities used to inform preclinical study design and support clinical translation.
Project consortium
Partners
The ERA4TB Consortium brings together a multi-disciplinary team with proven expertise and capabilities in TB drug development to profile and progress anti-TB compounds up to completion of Phase I.
The project consortium integrates 32 organizations, namely eight prestigious academic institutions (UC3M, UNIZAR, UU, EPFL, UKÖ, UNIPD, UPV, LUND), four non-profit organizations (IPP, IPL, iM4TB, BAR), nine public research organizations (BOR, CNR, IDMIT, SERMAS, PHE, NICE, SCI, LIOS, CIM – Sant Pau) and five highly skilled small-medium enterprises (SYNAPSE, C-Path, IBT, QPS, GRIT42), together with three EFPIA members (GSK, EVOTEC, Janssen), and three IMI2 Associated Partners (BMGF, TBA, DDU).
| Logo | Short name | Partners full name | Link |
|---|---|---|---|
 |
UC3M | University Carlos III Madrid | https://www.uc3m.es/Home |
 |
IPP | Institute Pasteur (Paris) | https://www.pasteur.fr/en/institut-pasteur |
 |
UNIZAR | University of Zaragoza / ARAID | www.unizar.es |
 |
IPL | Institute Pasteur de Lille Foundation | https://www.pasteur-lille.fr/5/research/units/ |
 |
SYNAPSE | Synapse Managers Partners | https://synapse-managers.com/ |
 |
BOR | Forschungszentrum Borstel | https://fz-borstel.de/index.php/de/ |
 |
IM4TB | Foundation Innovative Medicines for Tuberculosis | http://im4tb.org |
 |
C-Path | Critical Path Institute, Limited | https://c-path.eu/ |
 |
CNR | Consiglio Nazionale delle Richerche | https://www.iac.cnr.it/ |
 |
IDMIT | Infectious Diseases Models for Innovative Therapies | https://idmitcenter.fr/symposium/ |
 |
SERMAS | Instituto de Investigación Hospital Universitario La Paz | http://www.idipaz.es |
 |
UU | Uppsala University | https://www.uu.se/en |
 |
PHE | Public Health England- Department of Health | https://www.gov.uk/government/organisations/public-health-england/about |
 |
EPFL | École polytechnique fédérale de Lausanne | https://www.epfl.ch/labs/mckinney-lab/ |
 |
UKÖ | University of Köln | http://www.uni-koeln.de |
 |
UNIPD | University of Padova | https://www.unipd.it/en/ |
 |
UPV | University of Pavia | https://web.unipv.it |
 |
NICE | The National Institute for Health and Care Excellence | https://www.nice.org.uk/about |
 |
IBT | ImaBiotech | www.imabiotech.com |
 |
SCI | Sciensano | https://www.sciensano.be/en/about-sciensano/sciensanos-organogram/bacterial-diseases/tuberculosis-and-mycobacteria#want-to-know-more- |
 |
LIOS | Latvia Institute of Organic Synthesis | http://www.osi.lv/en/. |
 |
BAR | Bioaster Foundation de Coopération Scientifique | https://www.bioaster.org/bioaster/bioaster-community/ |
 |
QPS | QPS Netherlands BV | https://www.qps.com |
 |
LUND | Phase I Unit of Skane Hospital | https://sodrasjukvardsregionen.se/clinicaltrialunit/ |
 |
GSK | Glaxosmithkline Investigacion y Desarrollo SL | https://www.gsk.com/ |
 |
EVOTEC | Evotec International GmbH | https://www.evotec.com/en |
 |
Janssen | Janssen Pharmaceutica NV | https://www.janssen.com/ |
 |
BMGF | Bill & Melinda Gates Foundation | https://www.gatesfoundation.org/ |
 |
TBA | Global Alliance for TB Drug Development | https://www.tballiance.org/ |
 |
DDU | University of Dundee | http://www.drugdiscovery.dundee.ac.uk/ |
 |
GRIT42 | Grit systems | https://grit42.com |
 |
CIM – Sant Pau | IIB Sant Pau | http://www.recercasantpau.cat/en/ |
ERA4TB Project Technical Coordinator
Dr. Juan Jose Vaquero
University Carlos III de Madrid
Calle Madrid 126
28 903 Madrid, Spain
| This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, and in-kind support from EFPIA, Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee. https://www.imi.europa.eu/ |
